HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human placental mesenchymal stem cells of fetal origins-alleviated inflammation and fibrosis by attenuating MyD88 signaling in bleomycin-induced pulmonary fibrosis mice.

Abstract
Pulmonary fibrosis is a progressive lung disease that its pathogenic mechanism currently is incompletely understood. Toll-like receptor (TLR) signaling has recently been identified as a regulator of inflammation and pulmonary fibrosis. In addition, mesenchymal stem cells (MSCs) of different origins offer a great promise in treatment of idiopathic pulmonary fibrosis (IPF). However mechanisms of pathogenic roles of TLR signaling and therapeutic effects of MSCs in the IPF remain elusive. In present study, the involvement of TLR signaling and the therapeutic role of MSCs were interrogated in MyD88-deficient mice using human placental MSCs of fetal origins (hfPMSCs). The results showed an alleviated pulmonary inflammation and fibrosis in myeloid differentiation primary response gene 88 (MyD88)-deficient mice treated with bleomycin (BLM), accompanied with a reduced TGF-β signaling and production of pro-fibrotic cytokines, including TNF-α, IL-1β. An exposure of HLF1 lung fibroblasts, A549 epithelial cells and RAW264.7 macrophages to BLM led an increased expression of key components of MyD88 and TGF-β signaling cascades. Of interest, enforced expression and inhibition of MyD88 protein resulted in an enhanced and a reduced TGF-β signaling in above cells in the presence of BLM, respectively. However, the addition of TGF-β1 showed a marginally inhibitory effect on MyD88 signaling in these cells in the absence of BLM. Importantly, the administration of hfPMSCs could significantly attenuate BLM-induced pulmonary fibrosis in mice, along with a reduced hydroxyproline (HYP) deposition, MyD88 and TGF-β signaling activation, and production of pro-fibrotic cytokines. These results may suggest an importance of MyD88/TGF-β signaling axis in the tissue homeostasis and functional integrity of lung in response to injury, which may offer a novel target for treatment of pulmonary fibrosis.
AuthorsFeng Li, Fei Han, Hui Li, Jia Zhang, Xia Qiao, Juan Shi, Li Yang, Jianda Dong, Meihui Luo, Jun Wei, Xiaoming Liu
JournalMolecular immunology (Mol Immunol) Vol. 90 Pg. 11-21 (10 2017) ISSN: 1872-9142 [Electronic] England
PMID28662409 (Publication Type: Journal Article)
CopyrightCopyright © 2017 Elsevier Ltd. All rights reserved.
Chemical References
  • IL1B protein, mouse
  • Interleukin-1beta
  • Myd88 protein, mouse
  • Myeloid Differentiation Factor 88
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • Bleomycin
  • Hydroxyproline
Topics
  • A549 Cells
  • Animals
  • Bleomycin (toxicity)
  • Cell Line
  • Female
  • Humans
  • Hydroxyproline (metabolism)
  • Inflammation (pathology, therapy)
  • Interleukin-1beta (metabolism)
  • Mesenchymal Stem Cell Transplantation
  • Mesenchymal Stem Cells (cytology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myeloid Differentiation Factor 88 (antagonists & inhibitors, genetics, metabolism)
  • Placenta (cytology)
  • Pregnancy
  • Pulmonary Fibrosis (chemically induced, pathology, therapy)
  • Signal Transduction
  • Transforming Growth Factor beta (metabolism)
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: